

# PolyPhil™ next

Injectable Polynucleotides

## Minimally invasive aesthetic treatment

for a more radiant, hydrated and rejuvenated skin

### Indicated areas:

- Mid & lower face
- Neck & décolleté
- Hands

### Purpose:

**#1** As a standalone treatment, the **combined formulation** delivers a synergistic effect, providing an instant boost of hydration. Significantly **improves skin hydration** by fostering fibroblasts, contributing to the restoration and **enhancement of elasticity, trophism, firmness, tone**, and overall appearance. Plays a crucial role in the **remodelling of striae distensae and depressed scars** as part of personalised treatment protocols<sup>1</sup>.

**SET** Skin Enhancement Technique (SET) generates a synergistic effect and helps prepare the skin before other aesthetic procedures: laser, radio frequency, filler, peeling, needling and surgery.<sup>2</sup>

### Injection protocol and injection technique:<sup>2</sup>

Treatment	Suggested protocol	Injection technique
2 ml per session	One session every 14 or 21 days for a total of:  3 sessions - normal skin  4 sessions for advanced ageing skin	Needle microdroplet or linear retrograde



**Concentration:** PN-HPT® 20mg/2ml non-crosslinked hyaluronic acid 20mg/2ml mannitol to slow down hyaluronic acid degradation<sup>3</sup> | **Pack:** 1 x 2 ml pre-filled syringe

**Needle:** 2 x 30G x 1/2, 13 mm | **Depth of injection:** intradermal

# Exploring the potential of PolyPhil Next in facial middle third rejuvenation.<sup>4</sup>

An open-design, exploratory prospective cohort study in 40 real-life ambulatorily treated women has been performed to probe the value of PolyPhil Next in middle third rejuvenation.

## Treatment protocol:

At baseline treatment with intradermal injections of 2ml PolyPhil next, containing 10mg/ml Polynucleotides and 10mg/ml non-crossed link hyaluronic acid, and 200 mM mannitol.

After 3 weeks treatment with intradermal injection of 2ml of PolyPhil 20mg/ml

After 6 weeks treatment with intradermal injections of 2ml PolyPhil next, containing 10mg/ml Polynucleotides and 10mg/ml non-crossed link hyaluronic acid, and 200 mM mannitol.

## Efficacy:

- Significant improvement of overall skin quality and texture (from  $7.0 \pm 1.06$  at baseline session to  $7.8 \pm 0.99$  at follow-up)
- Significant improvements of wrinkles and skin roughness, elasticity, and brightness (-17.1%, +39.6%, and +51.1%, respectively)
- The individual satisfaction score was  $8.0 \pm 0.87$  out of a theoretical maximum of 10

## Safety:

- All side effects were no more severe than mild and transient discomfort, irritation or pain at the injection site.
- No systemic adverse events have been reported



HB 3D Baseline Pre & Post comparison knee scar

Images courtesy of Prof. Syed Haq



DM 3D Baseline Pre & Post comparison. R & L Hands

<sup>1</sup> PolyPhil next IFU | <sup>2</sup> Cavallini M, Bartoletti E, Maioli L, Massironi A, Pia Palmieri I, Papagni M et al. Consensus report on the use of PN-HPT™ (polynucleotides highly purified technology) in aesthetic medicine. *J Cosmet Dermatol.* 2021 Mar;20(3):922-928. doi: 10.1111/jocd.13679. Epub 2020 Sep 21. PMID: 32799391; PMCID: PMC7984045 | <sup>3</sup> Mendoza G, Alvarez AI, Pulido MM, Molina AJ, Merino G, Real R et al. Inhibitory effects of different antioxidants on hyaluronan depolymerization. *Carbohydr Res.* 2007 Jan 15;342(1):96-102. doi: 10.1016/j.carres.2006.10.027. Epub 2006 Nov 2. PMID: 17123492. | <sup>4</sup> Data on file



The medical practitioner confirms having informed the patient of a likely risk associated with the use of the medical device in line with its intended use. For risks and adverse events associated with the use of the product consult the instructions of use.